ChemCD Blockbuster launch:Concern ChemCD Wechat, to get a three-month Gold Sponsor qualification

  • Wechat,Gold Sponsor,service,suppliers


Click Here to Redeem " Gold Sponsor "


Active process

Scan QR code, Focus on ChemCD WechatGet CD keyLogin in www.chemcd.comClick award area enter the CD key Information confirmedService starts


Prizes Conversion Conditions

1. If you want to enjoy this special service, which need you already became one of the ChemCD suppliers.

2. If you had purchased ChemCD gold sponsor services, you only need to get a redemption code, which can get a three-month gold sponsor qualification directly. Other ordinary users, you can add the ChemCD links to your business web site, after we confirm that, you also can get gold sponsorship for three months.


What is the Gold Sponsor

Gold Sponsor is a promotional product services. After users buy the product, you will become ChemCD gold sponsors, which you can release more than 1500 products. At the same time, you can set the corresponding number of products as advantage products, showing in the first page of the supplier list.


Service comparison for Gold Sponsor


Regular member

Gold Sponsor

The number of products to release

1500

1500 +

Advantage product number

-

50 +

Batch Import Products

Batch refresh product features

-

Release supply-demand information

The identifying of noble

-

The ranking of products on home page

-

The number of enquiry be checked every day

5

Unlimited

Get the enquiry automatically

-

The text ads on home page

-

Displaying the key products on home page

-

Support the QQ, MSN

-


Your advantage to be a Gold Sponsor is: Bigger platform, More enquiry, Higher transaction rate!


Event Time

From June 20th 2014 to June 30th 2014


Contact us

E-mailservice@chemcd.com

Tel0571-81025280

QQ320204646


ChemCD Product Price List

Product release number

Advantage product number

Price (RMB)/year

500

50

1500

1,000

60

1800

1,500

70

2100

2,000

80

2400

3,000

95

3000

4,000

110

3500

5,000

125

4000

6,000

140

4500

8,000

160

5500

10,000

180

6500

12,000

200

7500

15,000

240

9000


This link:http://www.chemcd.com/news/1008.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.